Hong Kong Studies Show Tyzeka Superior To Epivir, Hepsera In Fighting HBV (China)
This article was originally published in PharmAsia News
Executive Summary
A pair of university studies in Hong Kong conclude Idenix's Tyzeka (telbivudine) for treating chronic hepatitis B is better than commonly prescribed treatments for suppressing the hepatitis B virus. The studies compared GlaxoSmithKline's Epivir (lamivudine) and Gilead's Hepsera (adefovir dipivoxil) with Tyzeka and said 60 percent of patients on the Idenix drug ended up with non-detectable HBV in their blood. The studies in the New England Journal of Medicine and the Annals of Internal Medicine found 40 percent of patients on the other two drugs achieved that outcome after a year. Tyzeka is priced between the prices of the other two. (Click here for more
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.